Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study

Diabetes, Obesity and Metabolism

Volumn 12, Issue 9, 2010, Pages 780-789

  Matthews, D R ^a   Dejager, S ^b   Ahren, B ^c   Fonseca, V ^d   Ferrannini, E ^e   Couturier, A ^f   Foley, J E ^f   Zinman, B ^g  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b NOVARTIS PHARMA K K   (Japan)

^c LUND UNIVERSITY   (Sweden)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF PISA   (Italy)

^f NOVARTIS PHARMA AG   (Switzerland)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

DPP 4 inhibitor; Elderly; Glimepiride; Hypoglycaemia; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIMEPIRIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; TRIACYLGLYCEROL; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BALANCE DISORDER; BRONCHITIS; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; COULOMETRY; DIARRHEA; DISEASE DURATION; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUNGER; HYPERHIDROSIS; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; LIMB PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MOTION SICKNESS; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SYNCOPE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UNSTEADINESS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VISUAL DISORDER; WEIGHT GAIN;

EID: 77955048324     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01233.x     Document Type: Article

References (34)

1. Rosenstock J, Foley JE, Rendell M. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008, 31:30-35.
2. Azuma K, Radikova Z, Mancino J. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:459-464.
3. D'Alessio DA, Denney AM, Hermiller LM. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:81-88.
4. Ahren B, Schweizer A, Dejager S. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:1236-1243.
5. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008, 10:82-90.
6. Ferrannini E, Fonseca V, Zinman B. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11:157-166.
7. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008, 40:427-430.
8. Goke B, Hershon K, Kerr D. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008, 40:892-895.
9. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009, 83:233-240.
10. Pan C, Yang W, Barona JP. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-441.
11. Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:571-578.
12. Scherbaum WA, Schweizer A, Mari A. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10:1114-1124.
13. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007, 24:955-961.
14. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009, 11:804-812.
15. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:506-515.
16. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009, 41:368-373.
17. Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med 2002, 19:465-469.
18. Ahren B, Foley JE, Ferrannini E. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010, 33:730-732.
19. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009, 8:573-584.
20. Pratley RE, Schweizer A, Rosenstock J. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008, 10:931-938.
21. Balas B, Baig MR, Watson C. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007, 92:1249-1255.
22. Bunck MC, Diamant M, Corner A. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762-768.
23. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28:1936-1940.
24. Utzschneider KM, Tong J, Montgomery B. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008, 31:108-113.
25. Boschmann M, Engeli S, Dobberstein K. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009, 94:846-852.
26. Kahn SE, Haffner SM, Heise MA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
27. Basu R, Breda E, Oberg AL. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003, 52:1738-1748.
28. Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diabetes Metab 2005, 31:5S27-5S34.
29. Thearle M, Brillantes AM. Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity. Curr Opin Clin Nutr Metab Care 2005, 8:9-16.
30. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008, 25:245-254.
31. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008, 57:3169-3176.
32. Lassmann-Vague V. Hypoglycaemia in elderly diabetic patients. Diabetes Metab 2005, 31:5S53-5S57.
33. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 2006, 355:2477-2480.
34. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.